Tevogen Bio Holdings Inc. (TVGN)
NASDAQ: TVGN · Real-Time Price · USD
1.290
-0.050 (-3.73%)
At close: May 30, 2025, 4:00 PM
1.320
+0.030 (2.33%)
After-hours: May 30, 2025, 7:45 PM EDT
Company Description
Tevogen Bio Holdings Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders.
The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients.
It is also developing TVGN 920 for treating cervical cancer; TVGN 960 for treating oropharyngeal cancer; TVGN 601 for treating MS; and TVGN 930 for treating EBV-associated lymphomas.
The company was founded in 2020 and is headquartered in Warren, New Jersey.
Tevogen Bio Holdings Inc.
| Country | United States |
| Founded | 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 18 |
| CEO | Ryan Saadi |
Contact Details
Address: 15 Independence Boulevard, Suite #410 Warren, New Jersey 07059 United States | |
| Phone | 877 838 6434 |
| Website | tevogen.com |
Stock Details
| Ticker Symbol | TVGN |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001860871 |
| CUSIP Number | 88165K101 |
| ISIN Number | US88165K1016 |
| Employer ID | 98-1597194 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Ryan H. Saadi M.D., M.P.H, M.P.H. | Co-Founder, Chief Executive Officer and Chairperson |
| Kirti Desai CPA | Chief Financial Officer |
| Dr. Neal Flomenberg M.D. | Chief Scientific Officer and Global Research & Development Lead |
| Stephen Chen M.B.A. | Chief Technical Officer |
| Mittul Mehta | Chief Information Officer and Head of Tevogen.ai |
| Tapan V. Shah | Head of Investor Relations and Corporate Development |
| Sadiq Khan M.B.A. | Chief Commercial Officer and Interim Head of Tevogen Generics |
| David E. Banko CPA | Global Head of Government Affairs and Patient Access |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 14, 2025 | 424B3 | Prospectus |
| May 14, 2025 | 10-Q | Quarterly Report |
| May 7, 2025 | 424B3 | Prospectus |
| May 2, 2025 | EFFECT | Notice of Effectiveness |
| May 1, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Apr 30, 2025 | POS AM | Post-Effective amendments for registration statement |
| Apr 30, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 30, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 25, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 25, 2025 | 8-K | Current Report |